Moxifloxacin

Synonyme: Avelox, Avalox, Moxeza, Vigamox, BAY 12-8039, 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid

Moxifloxacin is a fourth-generation fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV. Its C-8 methoxy group and bulky C-7 azabicyclic side chain enhance activity against Gram-positive pathogens and reduce the selection of resistant mutants compared with earlier fluoroquinolones. The fluorine at position 6 improves tissue penetration and intracellular accumulation.

As a synthetic API, moxifloxacin is manufactured through a multi-step process starting from fluoroquinolone intermediates. It is available as the free base or as hydrochloride and is typically supplied in high-purity crystalline form suitable for oral and injectable dosage forms. The material is classified as a prescription antibiotic and is subject to strict regulatory oversight.

Moxifloxacin is used in the treatment of respiratory tract infections, skin infections, and intra-abdominal infections. Its broad spectrum and favorable pharmacokinetics make it a valuable API for pharmaceutical manufacturers. It is also employed as a reference standard in analytical laboratories.

Chemical Structure & Properties

Moxifloxacin features a 4-oxo-1,4-dihydroquinoline-3-carboxylic acid core with a cyclopropyl group at N-1, a fluoro substituent at C-6, a methoxy at C-8, and a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl moiety at C-7. This structure confers a zwitterionic character, with pKa values of 6.0 and 9.3, leading to pH-dependent solubility. The compound is stable under normal storage conditions but should be protected from light and moisture.

Mechanism of Action

• DNA gyrase inhibition: Moxifloxacin binds to the DNA gyrase–DNA complex, blocking the re-ligation step of bacterial DNA replication, leading to double-strand breaks and cell death.
• Topoisomerase IV inhibition: It also targets topoisomerase IV, particularly in Gram-positive bacteria, enhancing its bactericidal effect.
• Concentration-dependent killing: The area under the curve to MIC ratio (AUC/MIC) is the primary pharmacodynamic parameter predicting efficacy.
• Post-antibiotic effect: Moxifloxacin exhibits a prolonged post-antibiotic effect against both Gram-positive and Gram-negative pathogens.

Quality Specifications (QC Tests)

Supply & Documentation

• Capacity: 5 metric tons per month
• Lieferzeit: 3–5 Werktage (Lagerware)
• Dokumentation: COA, MSDS, TDS, and regulatory support available upon request
• Verpackung: 25 kg fiber drum with double polyethylene liner, or as per customer requirements

Häufig gestellte Fragen

What is the minimum order quantity (MOQ)?

Our standard MOQ is 1 kg. For smaller quantities, please contact us to discuss your requirements.

How long does delivery take?

For stock items, delivery is within 3-5 business days after order confirmation.

Can you provide a COA and samples?

Yes, we provide a COA for each batch. Samples are available upon request; please contact our sales team for arrangements.

Contact & Ordering Information

• Company: LyvBio Co., Ltd.
• Address: Room 5-0203, Courtyard 205, Lianhu District, Xi’an, Shaanxi, China
• Email: info@lyvbio.com
• Phone: +86-29-65816888

send us your specification for a quotation.